Metritrack
MetriTrack develops hand-held ultrasound devices for precise, efficient breast cancer diagnosis, founded in 2014, Illinois-based.
Founded
2014MetriTrack develops hand-held ultrasound devices for precise, efficient breast cancer diagnosis, founded in 2014, Illinois-based.
MetriTrack, founded in 2014 and headquartered in Hillside, Illinois, is dedicated to revolutionizing breast cancer diagnostics. The company's core mission is to enhance the precision and efficiency of breast cancer detection, particularly in women with dense breast tissue. MetriTrack's flagship product, the BVN G-1000, is a hand-held ultrasound device that employs proprietary automated techniques to provide accurate visual images for diagnosis. This innovation aims to address the limitations of traditional mammograms and improve early detection rates.
Notable figures associated with MetriTrack include its founders and key investors who have supported its mission to save lives through advanced medical technology. The company has achieved significant milestones, including the development and deployment of its BVN G-1000 device, which has been instrumental in identifying previously undetectable breast cancers. MetriTrack's impact is profound, as it addresses a critical gap in breast cancer screening, potentially benefiting over 18 million women in the U.S. who require supplemental ultrasound diagnostics.
Companies similar to Metritrack include Delphinus Medical Technologies, Caia, Malcova and Metre.
Metritrack was founded in 2014.
Metritrack's headquarters is located in Hillside, IL, US.
Metritrack's most recent funding round was for $1.5M (USD) in January 2019.
As of Jan 27, 2019, Metritrack has disclosed funding of $2.1M (USD). Undisclosed round amounts are excluded.
Metritrack has 12 employees as of Feb 5, 2024.
Metre
metre.ai
